Which federal agency does American Pharmacists Association (APhA) comment on most?

American Pharmacists Association (APhA) is most active at the Food and Drug Administration.

← OpenPolis Sign in

American Pharmacists Association (APhA)

Unclaimed

Industry

Nonprofit Organization Management

Staff

140

2215 Constitution Avenue Northwest, Washington, DC

Phone

+1 202-628-4410

Website

pharmacist.com

Engagement overview

American Pharmacists Association (APhA) has filed 230 public comments across 202 dockets at 17 federal agencies, most actively at the Food and Drug Administration.

American Pharmacists Association (APhA)

Engagement overview

Is this your organization?

Agency footprint

Dockets (202)

Expanding Access to State Prescription Drug Monitoring Programs (AS73)

Drug Repurposing for Unmet Medical Needs; Request for Information

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

NDA Comment Request Notice

Modernizing NRC Regulations for Byproduct Material Use

Drinking Water Contaminant Candidate List 6 (CCL 6)

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – United States (U.S.) 2026-2027 Formula for COVID-19 Vaccine Composition.

Increasing Availability of Nonprescription Drugs; Request for Information

Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability

Developmental Studies to Improve the National Health Care Surveys

Improving Transparency Into Pharmacy Benefit Manager Fee Disclosure

Developing Specifications for In-Home Disposal Systems for Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

FTC Seeks Analysis To Aid Public Comment on Agreement Containing Consent Order; Express Scripts; Docket No. 9437

Meeting of the Advisory Committee on Immunization Practices 3/18-3/19

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – United States (U.S.) 2026-2027 Influenza Vaccine Strain Composition

Health Data, Technology, and Interoperability: ASTP/ONC Deregulatory Actions To Unleash Prosperity

Request for Information: Accelerating the Adoption and Use of Artificial Intelligence as Part of Clinical Care

Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information

Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use

Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine; Public Workshop; Request for Comments

Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment under the Drug Supply Chain Security Act

Meeting of the Advisory Committee on Immunization Practices - December 2025

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

Meeting of the Advisory Committee on Immunization Practices - September 2025

Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs from Bulk Drug Substances

Use of Orally Ingestible Unapproved Prescription Drug Products Containing Fluoride in the Pediatric Population; Public Meeting; Establishment of a Public Docket; Request for Comments

Request for Information Regarding the Prescription Drug Machine-Readable File Requirement in the Transparency in Coverage Final Rule

ACIP - Committee Meeting (June 25-26, 2025)

Notice of Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients

Request for Public Comment Regarding Reducing Anti-Competitive Regulatory Barriers

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments -- 2025-2026 formula for COVID-19 vaccines for use in the United States: Meeting Date: May 22, 2025.

April 15-16, 2025, Meeting of the Advisory Committee on Immunization Practices

Proposed Modifications to the HIPAA Security Rule to Strengthen the Cybersecurity of ePHI

Enhancing Coverage of Preventive Services under the Affordable Care Act

Health Data, Technology, and Interoperability: Patient Engagement, Information Sharing, and Public Health Interoperability

Labor Certification for Permanent Employment of Foreign Workers in the United States; Modernizing Schedule A To Include Consideration of Additional Occupations in Science, Technology, Engineering, and Mathematics (STEM) and Non-STEM Occupations

Medication Guides: Patient Medication Information; Proposed Rule

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

National Diabetes Prevention Program Diabetes Prevention Recognition Program

CDRH Seeks public comment: Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 Diabetes

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act

Request for Information; Coverage of Over-the-Counter Preventive Services

Labeling for Biosimilar Products

Reauthorization of the Over-the-Counter Monograph Drug User Fee program; Public Meeting; Request for Comments

Draft Merger Guidelines for Public Comment

Development of Small Dispensers Assessment under the Drug Supply Chain Security Act; Request for Comments

Nonprescription Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

In-Home Safe Disposal Systems; Request for Information

Petitioner requesting FDA to issue a final rule removing oral phenylephrine from the Final Monograph for OTC nasal decongestant drug products and to remove phenylephrine bitartrate from the 2006 amendment.

HIPAA Privacy Rule to Support Reproductive Health Care Privacy

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

DSCSA Implementation and Readiness Efforts for 2023; Public Meeting; Request for Comments

DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information; Availability

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

Identifying Trading Partners Under the Drug Supply Chain Security Act

National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Solicitation for Public Comments on the Impact of Prescription Benefit Managers’ Business Practices

Proposed 2022 CDC Clinical Practice Guideline for Prescribing Opioids

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

Generic Drug User Fee Amendments; Public Meeting; Request for Comments

Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act

Biosimilar User Fee Act

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

Interventions to Prevent Work-Related Stress and Support Health Worker Mental Health; Request for Information

Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

COVID-19 Emergency Temporary Standard Rulemaking

Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act

Methods and Learning Practices for Advancing Equity in Support for Underserved Communities Through Government

The Drug Supply Chain Security Act Pilot Project Program and Enhanced Drug Distribution Security; Public Meeting; Request for Comments

Harm Reduction Toolkit for Non-Prescription Syringe Sales in Community Pharmacies

Dual Agency - HHS Federal Register Notices (FRN) without a docket ID which includes FDA data or supported related material